Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Springfield, Missouri 65802


This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).


Inclusion Criteria: - Postmenopausal female, in good health (at least 5 years since last menses) - Age ≥45 and ≤70 - Weight + or - 20% of the Metropolitan Life weight table - Plasma C-terminal telopeptide of type I collagen (CTx-1) ≥ 0.25 ng/mL - Total calcium (Ca++), phosphorus (P), and magnesium (Mg++) within normal range - Willing and able to comply with all study requirements - Willing and able to sign written informed consent - Negative urine pregnancy test at screening - Negative Screen for Hepatitis B and C, human immunodeficiency virus (HIV) and drugs of abuse Exclusion Criteria: - History of parathyroid, thyroid, pituitary or adrenal diseases - History of musculoskeletal disease - History of gastro-esophageal reflux disease (GERD) or other significant gastrointestinal disorders - History of cancer within 5 years of enrollment other than basal cell carcinoma - History of regular use of non-steroidal anti-inflammatory drugs (NSAID) - History of surgery within 60 days of enrollment - History of hypersensitivity or allergies (other than seasonal allergies) within 5 years of enrollment including known sensitivity to the active ingredients or the excipients in the study medications - Use of concomitant medications other than acetaminophen within 7 days of enrollment or anticipated need to use such concomitant medications during the study - Use of bisphosphonates within 6 months, selective selective estrogen receptor modulators (SERMS), estrogen or estrogen-like drugs 2 months, or calcitonin 1 month - Presence of any clinically significant illness - Unwilling or unable to comply with all study requirements - Unwilling or unable to sign written, informed consent - History of drug or alcohol abuse - Participation in any clinical study of an investigational drug within 60 days of enrollment - Plasma CTx-1 less than 0.25 ng/mL



Primary Contact:

Principal Investigator
Thomas Legg, D.O.
Bio-Kinetic Clinical Applications, Inc.

Backup Contact:


Location Contact:

Springfield, Missouri 65802
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.